A Collaborative Analysis of Data from Cohorts in Thailand, South Africa, Botswana, and the United Kingdom International Collaborative Study of Pediatric.

Slides:



Advertisements
Similar presentations
HIV Counselling and Testing
Advertisements

Draft Generic Protocol: Measuring Impact and Effectiveness of National Programs for Prevention of Mother-To-Child HIV Transmission at Population-Level.
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA,
1 Effect of Maternal HAART on Postnatal HIV-1 Transmission after Cessation of Extended Infant Antiretroviral Prophylaxis Taha Taha 1, Johnstone Kumwenda.
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Effectiveness of the National PMTCT Program in Rwanda
Association between feeding style and weight gain in infants aged 2-7 months Mihrshahi S* 1,2, Daniels L A 1,2, Jansen E 1,2, Battistutta D 2, Wilson JL.
P1060 commentary Philippa Musoke MBChB Makerere University –Johns Hopkins University Research Collaboration, Kampala Uganda.
HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States Ma. Teresa C. Ambat, MD Asst Professor TTUHSC-Neonatology12/2/2008.
Perinatal HIV Case Series Reports for Births in Presenter: Elvia Ledezma Texas Department of State Health Services.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.
Laboratories Branch, MOHLTC, IMC – 2001 The epidemiology of HIV infection among persons from HIV-endemic countries in Ontario: Update to 2002 Robert S.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.
1 Potential Impact and Cost-Effectiveness of the 2009 “Rapid Advice” PMTCT Guidelines — 15 Resource-Limited Countries, 2010 Andrew F. Auld, Omotayo Bolu,
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Pediatric ID Previous presentation by Susan Schuval, MD
Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated women, compared to HIV-uninfected women* Hélène Côté* 1,2, Evelyn Maan.
Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Nomsa Mulima 17 th July 2011 Effectiveness of the PMTCT program in Swaziland.
1 Diagnosis of HIV Infection in Children HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.
Generic protocol for national population-based impact evaluation of national programs for PMTCT at 6 weeks post-partum Thu-Ha Dinh, MD., MS., US CDC/GAP.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health,
CARE OF THE NEONATE. August Infants Born to Mothers with Unknown HIV Infection Status (1) Determine possible HIV exposure and need.
Operational effectiveness of single- dose Nevirapine in preventing mother-to-child transmission of HIV Mark Colvin, Mickey Chopra, Tanya Doherty, Debra.
8èmes Rencontres Nord-Sud Avelin Aghokeng IRD-UMI233 & University of Montpellier I Yaoundé-Cameroon Avelin Aghokeng IRD-UMI233 & University of Montpellier.
Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
MATERIAL & METHODS SECTION PREPARATION (IN THE HEALTH RESEARCH PROPOSAL) DR. HAYFAA A. WAHBI ASSISTANT PROFESSOR, CHAIR OF EBHC & KT COLLEGE OF MEDICINE.
Transmission of HIV from mother to fetus. - is not simply one of the major health problems today, but also a big problem in the field of human rights.
MTN-016 TRAINING Infant HIV Testing Urvi M Parikh, Ph.D. University of Pittsburgh Pittsburgh, PA USA.
Alison Drake International AIDS Society Conference July 18, 2011 Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum: results.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Late maternal HIV testing, HCMC Chi K. Nguyen 1, Haily T. Pham 2, ThuVan T. Tieu 2, Chinh.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
A Call to Action Children – The missing face of AIDS.
Paz Bailey G 1, Sternberg M 1, Puren AJ 2, Markowitz LE 1, Ballard R 1, Delany S 3, Hawkes S 4, Nwanyanwu O 1, Ryan C 1, and Lewis DA 5 1. NCHHSTP, CDC.
Cascade of Prevention of Mother-to-Child Transmission of HIV (PMTCT) for Option B+ Transition: Findings from a Cohort of a Nationally Representative Sample.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Illness during pregnancy is associated with in utero human immunodeficiency virus type-1 transmission Carey Farquhar, MD, MPH University of Washington/University.
Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) ( )
Background Since 1996, HAART progressively replaced ZDV monotherapy to prevent mother-to- child HIV transmission  Is HAART associated with low birthweight.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
HIV Point of Care tests in Babies Study (BABY) Operational evaluation of HIV Point of Care tests for very early infant HIV diagnostics in infants born.
Are we there yet? Spatial-temporal trend of mother to child HIV transmission in western Kenya, Anthony Waruru, Thomas Achia, Hellen Muttai, Lucy.
IMPAACT 2010 Eligibility Criteria
Emory University School of Medicine Department of Medicine
Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,
Module 4 (e) Pregnancy and Breast Feeding
Earlier treatment and lower mortality in infants Initiating ART at
IMPAACT 2010 Eligibility Criteria
VESTED Quiz Game
On behalf of The MTN-020/ASPIRE Study Team
VESTED Quiz Game
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Eligibility Criteria
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Cepheid Symposium, IAS 23rd July 2018
Assessment of the utilization of prevention of mother-to-child transmission of HIV services and health outcomes of infants born to HIV positive mothers.
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Dolutegravir in PEPFAR
Presentation transcript:

A Collaborative Analysis of Data from Cohorts in Thailand, South Africa, Botswana, and the United Kingdom International Collaborative Study of Pediatric Diagnostic Tests JULY 19, 2011 Time to DNA-PCR Positivity in Non-Breastfed HIV-Infected Infants (Primarily Non-B HIV Subtype)

Background Accurate diagnostic tests to detect HIV infection in infants are critical to ensure early treatment HIV DNA-PCR has imperfect sensitivity in the first two weeks of life Previous studies found that time to HIV DNA-PCR positivity increase by about 15% with ZDV prophylaxis compared with no antiretrovirals (ARV) Impact of combination ARV prophylaxis is not well characterized; no single cohort can adequately address this question

Goals Combine data from several cohorts of non- breastfeeding HIV-infected mother-infant pairs  Initial phase: cohorts with primarily non-B HIV subtype Estimate the time to DNA-PCR positivity in non-breastfed HIV-infected infants Assess differences in time to DNA-PCR positivity according to maternal/infant ARV regimen

Inclusion/Exclusion Criteria Inclusion criteria:  Infant HIV-infected and has at least one DNA- PCR result before age 3 months  Maternal HIV diagnosis before or within 1 month after birth Excluded diagnostic tests with missing result or missing age at time of blood draw Excluded one infant whose mother’s ARV exposure was unknown

Statistical Methods Used methods for interval-censored data  Timing of HIV infection uncertain; in interval between last negative and first positive DNA-PCR test Estimated the cumulative probability of DNA-PCR positivity according to age and ARV  Non-parametric methods; Turnbull algorithm, Wilcoxon test Exploratory regression modeling to adjust for potential confounders  Parametric methods; assumed Weibull distributions with proportional hazards; likelihood ratio test

Participating Cohorts CohortCountryBirth Years Number of Infants (Tests) MASHIBotswana (91) Infant Diagnostic Study South Africa (83) NSHPC/HPAUK (African origin) (181) PHPTThailand (678) Thai/CDCThailand (370) Total 432 (1403)

Infants Grouped by Most Complex Maternal/Infant ARV Infant ARV Prophylaxis Maternal ARV during Trimester of Delivery No ARV Single NRTI sdNVP (+/- ZDV)>3 ARVs No ARV Single NRTI sdNVP (+/- ZDV) >3 ARVs No ARV = Mother and infant did not receive ARV at any time (n=125) Single NRTI = Mother or infant received single NRTI (n=159) sdNVP (+/- ZDV) = Mother or infant received sdNVP +/- ZDV (n=105) >3 ARVS = Mother or infant received >3 ARVs (n=43)

Demographics No ARV (n=125) Single NRTI (n=159) sdNVP +/- ZDV (n=105) >3 ARVs (n=43) Year of Birth Country Where HIV Acquired Botswana South Africa00272 Zimbabwe83210 Nigeria4106 Other African Country75021 Thailand

Characteristics ( median [25 th -75 th percentile]) No ARV (n=123) Single NRTI (n=159) sdNVP +/- ZDV (n=79) >3 ARVs (n=43) P value (Kruskal- Wallis) Maternal CD4 Near Delivery 410 [ ] 296 [ ] 284 [ ] 290 [ ] < Maternal Viral Load Near Delivery 67,590 [26, ,174] 14,125 [2,963 – 39,363] 41,496 [12,448 – 94,575] 6,000 [ ,666] < Gestational Age at Delivery 39 [35-43] 38 [33-43] 38 [33-43] 37 [30-45] < Delivery Type: Vaginal CS no labor/ROM CS with labor/ROM 92% 2% 6% 78% 9% 13% 80% 5% 15% 25% 40% 35% <

Cumulative Probability of Positive DNA-PCR by Age (Non-Parametric) P value (Wilcoxon) = ARV Group Number of infants Birth- 1 day <14 days < 30 days <42 days <90 days <370 days No ARV Single NRTI sdNVP +/- ZDV >3 ARVs

Cumulative Probability of Positive DNA-PCR by Age (Subset: 143 infants negative at birth or day 1) P value (Wilcoxon) = ARV Group Number of infants <14 days <30 days <42 days <90 days <370 days No ARV Single NRTI sdNVP+/- ZDV >3 ARVs

Cumulative Probability of Positive DNA-PCR by Age (Parametric - separate Weibull models, unadjusted)

Adjustment for Confounders: Infants who Received ARV (Parametric, Proportional Hazards; HR >1 Means Earlier Positivity) ARV GroupUnadjusted Hazard Ratio [95% CI] Adjusted Hazard Ratio [95% CI] Single NRTI1.44 [1.00 – 2.09]1.44 [ ] sdNVP+/- ZDV1.56 [1.06 – 2.30]1.39 [ ] >3 ARVs 1.0 P value for ARV Group * *P value for CD4 = 0.80, viral load =0.89, gestational age=0.44, delivery type =0.91

Summary and Conclusions Lower DNA-PCR positivity at birth and greater increase in positivity by 14 days of age in HIV- infected, non-breastfed infants who had no ARV vs. those who had maternal or infant ARV  Suggests ARV prevents a large proportion of intrapartum transmission Nonparametric estimates of the probability of DNA- PCR positivity by age differed significantly according to ARV group  Time to DNA-PCR positivity was later with receipt of >3 ARVs than with single NRTI or sd-NVP (+/- ZDV)

Summary and Conclusions (2) In preliminary parametric regression modeling, the association between ARV group and time to positivity did not remain statistically significant  However, adjustment did not change the hazard ratios and the confidence intervals were mostly above 1.0  The small number of infants exposed to > 3 ARVs limited the statistical power to detect a difference; further study is needed Our results may have implications for scheduling final HIV PCR diagnostic testing, particularly when resources are limited.

International Collaborative Study of Pediatric Diagnostic Tests – Collaborators R. Balasubramanian D.E. Shapiro M.G. Fowler K. Dominguez P. Tookey J. Masters J. Tosswill M. Lallemant N. Ngo-Giang Huang M. McConnell P. Mock G. Sherman S. Lockman V. Novitsky P. Palumbo S. Nesheim B. Bohannon K. Rich M. Hughes We gratefully acknowledge the study participants